Systemic Lupus Erythematosus Clinical Trial
— FiNKLUPUSOfficial title:
Study of Neonatal Immunoglobulin G (IgG) Fc Receptor (FcRn) Expression in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT): Implication in the Pathophysiology of Systemic Lupus
This study evaluates the variation of expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT) and monocytes along with the surface expression of Fc gamma type II receptor (RII) and RIII in active or newly diagnosed lupus patients compared to inactive lupus patients.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 2029 |
Est. primary completion date | July 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years - Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and/or secondary Gougerot-Sjögren's - Lupus patient, newly diagnosed or known, untreated or in relapse - Lupus patient considered stable by the treating practitioner - Requiring blood sampling for follow-up Exclusion Criteria: - Main autoimmune disease other than lupus - Patient under legal protection, guardianship or curators - Opposition to data processing |
Country | Name | City | State |
---|---|---|---|
France | University Hospital | Tours |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Tours | Research Center for Respiratory Diseases, Inserm U1100 |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | FcRn Expression analysis in Circulating iNKT lymphocytes | by flow cytometry (mean fluorescence intensity) | through study completion, an average of 3 year | |
Primary | FcRn Expression analysis in circulating monocytes | by flow cytometry (mean fluorescence intensity) | through study completion, an average of 3 year | |
Primary | FcgammaRII Expression analysis in Circulating iNKT lymphocytes | by flow cytometry (mean fluorescence intensity) | through study completion, an average of 3 year | |
Primary | FcgammaRII Expression analysis in circulating monocytes | by flow cytometry (mean fluorescence intensity) | through study completion, an average of 3 year | |
Primary | FcgammaRIII Expression analysis in Circulating iNKT lymphocytes | by flow cytometry (mean fluorescence intensity) | through study completion, an average of 3 year | |
Primary | FcgammaRIII Expression analysis in in circulating monocytes | by flow cytometry (mean fluorescence intensity) | through study completion, an average of 3 year | |
Secondary | corticotherapy | data collected from patient medical file | through study completion, an average of 3 year | |
Secondary | hydroxychloroquine | data collected from patient medical file | through study completion, an average of 3 year | |
Secondary | immunosuppressants outside of biotherapy: methotrexate, azathioprine, mycophenolate mofetil | data collected from patient medical file | through study completion, an average of 3 year | |
Secondary | biotherapy: belimumab and rituximab | data collected from patient medical file | through study completion, an average of 3 year | |
Secondary | lupus disease activity | assessed with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). The score ranging from 0 (no activity) to 105 | through study completion, an average of 3 year | |
Secondary | albumin and IgG levels | by immunonephelometry | through study completion, an average of 3 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03843125 -
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
Recruiting |
NCT05698173 -
Systemic Lupus Erythematosus and Accelerated Aging
|
N/A | |
Active, not recruiting |
NCT01649765 -
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
|
Phase 2 | |
Recruiting |
NCT05704153 -
Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)
|
N/A | |
Completed |
NCT05048238 -
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
|
Phase 1 | |
Recruiting |
NCT06056778 -
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
|
||
Completed |
NCT04358302 -
Individual Patient Exposure and Response in Pediatric Lupus
|
N/A | |
Completed |
NCT03802578 -
The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients
|
N/A | |
Completed |
NCT02554019 -
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT04835883 -
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
|
Phase 2 | |
Terminated |
NCT02665364 -
Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00278538 -
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
Completed |
NCT03252587 -
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT02066311 -
Nelfinavir in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT01892748 -
Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
|
N/A | |
Terminated |
NCT01689025 -
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Unknown status |
NCT01712529 -
Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients
|
N/A | |
Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
Completed |
NCT00962832 -
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
|
Phase 2 |